scholarly journals Impact of body mass index on blood pressure levels in patients with polycystic ovary syndrome

2007 ◽  
Vol 51 (7) ◽  
pp. 1104-1109 ◽  
Author(s):  
Cristiano R.G. Barcellos ◽  
Michelle P. Rocha ◽  
Sylvia A.Y. Hayashida ◽  
Décio Mion Junior ◽  
Silvia G. Lage ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Body Mass Index ◽  
Polycystic Ovary Syndrome ◽  
Body Mass ◽  
Polycystic Ovary ◽  
Present Moment ◽  
Model Assessment ◽  
Ovary Syndrome ◽  
Significant Difference ◽  
The Impact

As there is controversy about the prevalence of hypertension in patients with polycystic ovary syndrome (PCOS) and, up to the present moment, no studies have evaluated the impact of body mass index (BMI) on blood pressure levels (BP) in these patients, we studied retrospectively sixty-nine patients with PCOS, with BMI of 29.0 ± 6.7 kg/m² and aged 25.6 ± 5.6 yr, subdivided into three groups according to BMI (normal, overweight and obese) and evaluated regarding BP (mercury sphygmomanometer), basal hormonal profile, fasting glucose, and insulin sensitivity (HOMA-IR). Mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) were normal (118.1 ± 17.0 and 74.7 ± 11.5 mmHg, respectively), with a hypertension prevalence of 20.3%. Of these patients, 78.6% were obese and 21.4% were overweight. When the groups were compared according to BMI, a significant increase in SBP and DBP was observed (higher in overweight and obese patients for SBP and higher in obese for DBP), as well as a significant progressive increase in glucose, insulin, homeostatic model assessment, and a significant progressive decline in LH levels. When the patients were subdivided as normotensive or hypertensive, a significant difference was observed only for BMI (28.2 ± 6.1 and 34.7 ± 8.6 kg/m², respectively; p = 0.007). In conclusion, we observed a significant and progressive impact of BMI on blood pressure levels in our patients with polycystic ovary syndrome.

scholarly journals Assessment of Psycho-emotional Distress Due to Age, Body Mass Index, and Marital Status in Polycystic Ovary Syndrome in North Indian Population

2020 ◽  
Vol 8 (4) ◽  
pp. 368-375
Author(s):  
Fauzia Tabassum ◽  
Hemali Heidi Sinha ◽  
Kavita Dhar ◽  
Chandra Jyoti ◽  
Md Sayeed Akhtar ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Weight ◽  
Polycystic Ovary Syndrome ◽  
Marital Status ◽  
Body Mass ◽  
Polycystic Ovary ◽  
Reproductive Age ◽  
Ovary Syndrome ◽  
Significant Difference ◽  
The Impact

Objectives: Polycystic ovary syndrome (PCOS) is a multifaceted endocrine disorder in reproductive age having a greater impact on health-related quality of life (HRQOL). The aim of this study was to find out PCOS demographics and its related HRQOL effects for improving psychological understanding in disease management. Materials and Methods: A prospective questionnaire-based study was conducted for a period of twelve months at All India Institute of Medical Sciences, Patna, India. The data of 100 PCOS cases were collected about socio-demographic status, clinical history, and dietary intake. Then, a validated PCOS questionnaire (PCOSQ) was used to observe the impact of PCOS symptoms on patients’ HRQOL. Results: The overall 57% and 48% of PCOS cases belonged to the age range of 20-30 years and had a body mass index (BMI) of >25-30, respectively. Based on the results, a significant difference was observed in the mean score of PCOSQ vs. marital status in PCOS cases with respect to emotion (P=0.039), body weight (P=0.002), and infertility (P=0.001). Furthermore, the result showed a significant difference in the domain of emotion (P=0.008), body hair (P=0.035), body weight (P<0.001), and infertility (P=0.018) among BMI group, and a high score was observed in the BMI group <18 in comparison to the other groups of BMI. Conclusions: In general, our findings indicated that infertility, emotions, and BMI had extremely higher impacts on the HRQOL of women suffering from PCOS although their educational status failed to affect HRQOL.

scholarly journals Effect of Metformin Therapy on Clinical and Hormonal Indices of Patients with Polycystic Ovary Syndrome

2021 ◽  
Vol 15 (5) ◽  
pp. 1522-1525
Author(s):  
S. Inayat ◽  
H. F. Khattak ◽  
M. G. Muhammad ◽  
K. Robeen ◽  
A. Inayat ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Body Mass Index ◽  
Body Weight ◽  
Polycystic Ovary Syndrome ◽  
Blood Sugar ◽  
Body Mass ◽  
Polycystic Ovary ◽  
Fasting Blood Sugar ◽  
Ovary Syndrome ◽  
Group Ii

Objective: The main objective of this study is to determine the efficacy of metformin therapy on clinical and hormonal indices of patients with polycystic ovary syndrome. Study Design: Randomized control trial Place and Duration: Study was conducted at Obstetrics & Gynaecology department of Northwest General Hospital and Research Center, Peshawar and Mian Rashid Hussain Shaheed Memorial Hospital, Pabbi for duration of nine months from March 2020 to November 2020. Methods: Total 100 patients of polycystic ovary syndrome were presented in this study. Patients were aged between 18 to 45years. Patients detailed demographics including age, body mass index and socio-economicstatus were recorded after taking informed written consent. Patients were divided into 2-groups, group I had 50 patients and received metformin (500 mg) three times a day and group II had 50 patients and received pioglitazone (30 mg) three times a day for 3months.Clinical (body weight, blood pressure (BP), and body mass index) and indices fasting blood sugar (FBS), serum triglyceride (TG), cholesterol, low-density lipoprotein, high-density lipoprotein, insulin, testosterone, and dehydroepiandrosterone (DHEA) were measured before and after therapy. Complete data was analyzed by SPSS 22.0 version. Results: Mean age of the patients in group I was 29.18 ± 2.25 years with mean BMI 26.14 ± 8.86 kg/m2 and in group II mean age was 29.8 ± 2.52 years with mean BMI 27.64 ± 7.68 kg/m2.Significantly decrease in blood pressure (systolic 105.41±8.57, diastolic 67.19±8.9), hair loss 20 (40%),oligomenorrhea 23 (46%), body weight 74.45±9.72, waist circumference and dehydroepiandrosterone (DHEA) 2.35±0.67 and as compared to group II. Only triglycerides gave results of reduction in group II 115.39±64.11. Among both groups serum insulin, acne, menstrual disturbance and fasting blood sugar were controlled after treatment. Conclusion: We concluded in this study that use of metformin in patients with polycystic ovary syndrome resulted in to decrease clinical body weight, blood pressure (BP), body mass index and hormonal indices with reduction of serum insulin, acne, menstrual disturbance and fasting blood sugar but pioglitazone was an alternative effective and reliable method in PCOS patients. Keywords: Polycystic ovary syndrome, Insulin resistance, Metformin, Pioglitazone

scholarly journals Insulin resistance in relation to clinical, endocrine and metabolic profile of infertile women with polycystic ovary syndrome

2021 ◽  
Vol 14 (1) ◽  
pp. 1-6
Author(s):  
Shakeela Ishrat ◽  
Marufa Hossain ◽  
Subrata Kumar Biswas
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Waist Circumference ◽  
Polycystic Ovary Syndrome ◽  
Body Mass ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Infertile Women ◽  
Significant Difference

The objective of this study is to explore how hyperinsulinemia and insulin resistance relate to the clinical, endocrine and metabolic factors in the infertile women with polycystic ovary syndrome. This study was conducted on 121 consecutive infertile women with polycystic ovary syndrome attending the Infertility unit from January 2017 to December 2017. They were divided into two groups: insulin resistant and insulin sensitive. There was significant difference in body mass index and waist circumference between the two groups. Serum lipids were not associated with insulin resistance. Hyperinsulinemia was significantly associated with metabolic syndrome. Reducing body mass index and waist circumference may improve insulin resistance in infertile women with polycystic ovary syndrome. Screening the infertile women with polycystic ovary syndrome for hyperinsulinemia and insulin resistance and subsequent counseling is recommended to address the long-term risks of metabolic syndrome.

scholarly journals Prevalence of abnormalities of glucose metabolism in patients with polycystic ovary syndrome

2007 ◽  
Vol 51 (4) ◽  
pp. 601-605 ◽  
Author(s):  
Cristiano R.G. Barcellos ◽  
Michelle P. Rocha ◽  
Sylvia A.Y. Hayashida ◽  
Márcia Nery ◽  
José A.M. Marcondes
Keyword(s):  
Body Mass Index ◽  
Glucose Metabolism ◽  
Polycystic Ovary Syndrome ◽  
Glucose Tolerance ◽  
Body Mass ◽  
Plasma Glucose ◽  
Polycystic Ovary ◽  
The Body ◽  
Ovary Syndrome ◽  
The Impact

Patients with polycystic ovary syndrome (PCOS) present a higher risk for abnormalities of glucose metabolism (AGM). For to study this in our population, we submitted 85 patients, with body mass index (BMI) of 28.5 ± 6.6 kg/m² and aged 25.5 ± 5.4 years old, to an oral glucose tolerance test (OGTT), and assessed the impact of BMI on the prevalence of impaired glucose tolerance (IGT) and of diabetes mellitus (DM). The states of glucose tolerance were classified considering fasting plasma glucose (FPG) according to the American Diabetes Association (ADA) criterion and plasma glucose at 120 minutes according to the Word Health Organization (WHO) criterion. According to the ADA criteria, 83.5% classified as normal and 16.5% as with AGM, with 15.3% presenting impaired fasting glucose and 1.2% DM, while according to the WHO criteria, 68.2% were classified as normal and 31.8% as with AGM, with 27.0% of them presenting IGT and 4.8% DM. Seventy-three percent of PCOS patients with IGT by WHO criterion had normal FPG by ADA criterion. The prevalence of AGM for both criteria increased with the body mass index. In conclusion, we found a higher prevalence of AGM in PCOS patients than that found in the general population, being the highest in obese patients. Glycemia at 120 minutes on the OGTT identified more patients with AGM than fasting glycemia. We recommended that the assessment of AGM must be done by the OGTT in all patients with PCOS.

In-Vitro Fertilization Outcome in Patients with Polycystic Ovary Syndrome: Role of Age and Maternal Body Weight

2021 ◽  
Vol 4 (5) ◽  
pp. 01-05
Author(s):  
Zahra Naeiji ◽  
Shahrzad Zademodares ◽  
Masoumeh Abbaspour ◽  
Maryam Anbarluei ◽  
Nayereh Rahmati ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Weight ◽  
Polycystic Ovary Syndrome ◽  
Body Mass ◽  
Polycystic Ovary ◽  
Maternal Body Mass Index ◽  
Ovary Syndrome ◽  
Maternal Body ◽  
Hormonal Profile ◽  
The Impact

Objective: to evaluate the impact of pre-gestational maternal age and body weight on the outcome of IVF in women with PCOS. Design: a retrospective study on women with PCOS undergoing IVF. Methods: Medical records of 200 known cases of polycystic ovary syndrome women treated in a third level referral center by the same therapeutic protocol were evaluated retrospectively. Demographic data, maternal body mass index, hormonal profile (LH, FSH, estradiol, anti-mullerian), IVF cycle parameters and outcome were documented. Patients were classified to three groups based on their body mass index (Normal: 18.5-24.9, overweight: 25-30, obese≥30). IVF cycle parameters and outcome were compared in these 3 groups. Effect of age was also evaluated by comparing the results in patients aged <35 and ≥35. Results: Mean age of patients was 32.5 (±5.2). 72 patients had normal BMI, 85 patients were overweighed and 43 cases were obese. Baseline hormonal profile was similar in 3 groups. Total dose of administered FSH were similar in 3 groups. Number of retrieved oocytes was statistically significant higher in patients with BMI>30 but the number of mature oocytes and number of embryos were statistically lower in this group. Size of follicles showed no statistically significant difference in 3 groups. Clinical pregnancy rate was statistically significant lower in patients with BMI>30 kg/m2 and age>35 years old. Conclusions: BMI>30 and age >35 years old has a statistically significant negative impact on IVF success rate.

Sign in / Sign up

Export Citation Format

Share Document